Despite the fact that our cohort was relatively small and grouping further reduced the number of patients, immunostaining performed on selected samples with or without chemotherapy treatment confirmed the ELISA results, as all treated tumor samples exhibited significantly lower SPOCK1 levels than those of non-treated tumor samples. This evidence concerns the gene SPOCK1 and neoplasm.